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Lipid transfer proteins (LTPs), particularly peach Pru p 3, are the most relevant plant food allergens in the 
South of Europe, and, therefore, their allergic properties have been extensively studied. However, neither 
T-cell epitopes nor their effect on the patients' T-cell response has been investigated in any member of the 
LTP panallergen family. The objective of the present study was to map the major T-cell epitopes of Pru p 3, as 
well as to evaluate their induced T-cell response in peach-allergic versus control subjects. Thus, peripheral 
blood mononuclear cells (PBMCs) from 18 peach-allergic patients and Pru p 3-specific T-cell lines (TCLs) 
from 9 of them were cultured with Pru p 3 and with a panel of 17 derived peptides (10-mer overlapping in 
5 amino acids representing the full sequence of Pru p 3). Proliferation in 5-day assays was carried out via 
tritiated-thymidine incorporation, while IL4 and IFN7 production was assessed via sandwich enzyme-
linked immunosorbent tests (ELISA) of TCL culture supernatants. The results were compared to those 
obtained from 10 non-peach allergic control volunteers. Two consecutive peptides showed the highest 
activation capacity. About 74% of PBMCs and TCLs recognized them, forming a single T-epitope: Pru p 
365-80- Additionally, other specific T-cell epitopes were observed. Pru p 32s-35 was detected by more than 
60% of TCLs from peach-allergic patients, and Pru p 345-55 only activated PBMCs from control subjects. 
Interestingly, TCLs from patients were associated with a Th2-type, whereas control TCLs presented a Thl-
type cytokine response. The major immunogenic T-cell epitope identified in Pru p 3, Pru p 365-so, is a 
good candidate to develop new vaccines for hypersensitivity reactions associated with LTP allergens from 
Rosaceae fruits. 
1. Introduction 
Peach is the major plant food involved in IgE-mediated reactions 
affecting the adult population from Southern European countries 
(Cuesta-Herranz et al, 1998; Kanny et al., 2001; Fernandez-Rivas 
et al, 2003). Accordingly, Pru p 3, its major allergen and lipid 
transfer protein (LTP) (Sanchez-Monge et al., 1999; Salcedo et al, 
2007), has been identified as the food allergen showing the high-
est prevalence of sensitization (positive-specific IgE) in the Spanish 
adult population with plant food allergy (Red Vegetalia, Instituto 
de Salud Carlos III, MSC, Spain; unpublished results). Clinically rel-
evant peach allergy is associated to Pru p 3 (Fernandez-Rivas et 
al., 2003), and this allergen also mediates cross-reactions between 
peach and some pollens, such as Artemisia vulgaris (Lombardero et 
al., 2004; Salcedo et al, 2007; Zuidmeer and van Ree, 2007) and 
Platanus acerifolia (Laurer et al., 2007), a relevant issue considering 
that most peach-allergic patients (around 80% in Spain) also suffer 
pollinosis (Cuesta-Herranz et al, 1999). 
Plant non-specific LTPs (type 1) are 9 kDa basic polypeptides, 
with a very compact and conserved 3-D structure stabilized by 
four disulphide bridges (Salcedo et al, 2007). This protein family 
is widely distributed throughout the plant kingdom, and has been 
related to defence mechanisms against plant pathogens and abiotic 
stress (Salcedo et al., 2007). Allergenic LTPs are highly resistant to 
protease digestion and heat treatments. They are usually associ-
ated to severe and systemic clinical symptoms and can be primary 
sensitizers by ingestion. They are also the main allergens of sev-
eral fruits, vegetables and nuts in the Mediterranean area (Salcedo 
et al., 2007). Altogether, these characteristics have led to propose 
LTPs, particularly Pru p 3, as a model of true food allergens (van Ree, 
2002; Salcedo et al., 2007). 
Cross-reactivity between Pru p 3 and other plant food LTP aller-
gens has been demonstrated (Diaz-Perales et al., 2000), and a 
recombinant form with immunological equivalence to natural Pru 
p 3 has been developed to be used in allergen component-based 
in vitro diagnosis (Diaz-Perales et al., 2003). Furthermore, both 
sequential and conformational IgE epitopes have been located in 
the 3-D structure of Pru p 3, and a potential hypoallergenic variant 
has been produced by site-directed mutagenesis (Garcia-Casado 
et al., 2003; Pacios et al., 2008). In contrast, no T-cell epitope of 
either Pru p 3 or any other allergenic LTP from plant foods has been 
identified so far. 
In spite of the high number of cross-reactions which have been 
related with peach (over 20), the only prescription for affected 
patients is the non-consumption of the foods involved. The scarce 
knowledge of food allergy mechanism prevents the development 
of new strategies for immunotherapy. Therefore, further research 
work is necessary to improve the diagnosis and treatment of this 
kind of hypersensitivity. The identification of major T-cell epitopes 
of the main plant food allergens is crucial for the development 
of T-cell targeted strategies (Glaspole et al., 2005). In the present 
study, PBMCs and TCLs from peach-allergic patients and non-
peach-allergic controls were stimulated with the allergen and with 
a set of overlapping peptides representing the full sequence of Pru 
p 3. The induced proliferation responses and cytokine production 
were measured. 
2. Materials and methods 
2.1. Peach-allergic patients and non-peach-allergic controls 
Peripheral blood from 18 peach-allergic patients sensitised to 
Pru p 3 and from 10 control volunteers non-allergic to peach was 
collected for this study. Patients were selected at the Servicio de 
Alergia, Fundacion Jimenez Diaz (Madrid) based on the following 
criteria: (1) a convincing clinical history of allergic reactions after 
peach ingestion. The presence of peach allergy was further con-
firmed in all selected patients by an open challenge test to peach, 
following a method previously described (Cuesta-Herranz et al., 
1998); (2) a positive skin prick test (SPT; EAACI, subcomittee of 
Skin Tests Allergen Standarization, 1989) response to a commercial 
peach extract (ALK-Abello, Madrid, Spain); and (3) sensitization to 
Pru p 3, ascertained by a positive SPT response to purified natural 
Pru p 3 (20 |jig/ml) and a significant specific IgE level to recombi-
nant Pru p 3 (5 |jtg/ml in solid phase; range: 0.304-2.757 OD units; 
cut-off value: mean+ 3 x S.D. = 0.189 to bovine serum albumin used 
as negative control) determined by an ELISA assay as previously 
reported (Diaz-Perales et al., 2003). Fourteen out of the 18 selected 
patients showed oral allergy syndrome (OAS), 3 had systemic reac-
tions and associated OAS and 1 had exclusively systemic symptoms. 
According to their lack of reaction after peach ingestion, a nega-
tive SPT to a commercial peach extract (ALK-Abello, Madrid, Spain), 
and non-sensitized to Pru p 3, the 10 non-allergic to peach con-
trol volunteers confirmed non-IgE to recombinant Pru p 3 (range: 
0.000-0.088 OD units), determined by the ELISA assay (see above). 
Seven out of the 10 control subj ects were non-atopic, 2 were allergic 
to grass {Phleum pratense) pollen and 1 was allergic to wasp venom. 
A written IFNormed consent was obtained from both patients 
and controls and the study was approved by the Ethics Committee 
of Fundacion Jimenez Diaz (Madrid). 
2.2. Purified Pru p 3 and synthetic Pru p 3-derived peptides 
Natural Pru p 3 was isolated from peach peel and its recombinant 
form from cultured supernatants of transformed Pichiapastoris cells 
as described by Diaz-Perales et al. (2003). 
A panel of 17 decapeptides was synthesized by following the 
amino acid sequence of Pru p 3. Peptides of 10-mer (overlapping 
in 5 amino acids) were produced by EZBiolabs (Westfield, IN, USA). 
The stock of each peptide was suspended in DMSO (10 mg/ml), and 
then diluted to 1 mg/ml in PBS buffer (0.1 M sodium phosphate, 
0.15 M NaCl, pH 7.4) before added to the cell cultures. DMSO or PBS 
buffer did not affect the proliferation of PBMC or TCL cultures (data 
not shown). 
2.3. Proliferation assays with PBMCs 
PBMCs were freshly isolated from 100 ml of blood subjected to 
density gradient centrifugation on Lymphoprep (Axis-Shield, Oslo, 
Norway). Cultures were established in triplicate in 96-well plates 
(Costar, NY, USA) at 5 x 105 cells per well for proliferation analy-
sis in a total volume of 200 JULI of RPMI media (Invitrogen, Paisley, 
UK), supplemented with 10% (v/v) of fetal calf serum (Invitro-
gen), 0.02 mM mercaptoethanol, 2mM of glutamine, and 10 mM 
HEPES, in the presence of 10 |jig/ml of Pru p 3 or 1 |jig/ml of 
each peptide, for 5 days at 37°C, in a 5% CO2 humidified atmo-
sphere. During the last 16 h, [3H]-thymidine (0.5 uXi/well) was 
added, and the incorporated radioactivity was measured by scin-
tillation counting. The concentrations of Pru p 3 and synthetic 
peptides were determined by dose-response experiments using 
PBMCs from two different patients and 0-50 |jig/ml of Pru p 3 or 
each peptide. These concentrations were similar to those previ-
ously published for other allergens (Ebner et al., 1995; Zeiler et al., 
1999; Jahn-Schmidetal., 2002). Phytohemagglutinin-L from Phase-
olus vulgaris (PHA; 1 pg/ml; Roche, Mannheim, Germany) was used 
as a positive control to evaluate the proliferative response of PBMC 
cultures. 
The stimulation index (SI) was calculated as the ratio between 
counts of antigen-stimulated cultures and counts without any acti-
vator. A SI > 2 was considered a positive value for PBMCs. 
2.4. Pru p 3-specific TCLs 
PBMCs (2 x 106 cells per well; 24-well plates) were treated with 
10|jLg/ml of Pru p 3 in a RPMI supplemented media (see above). 
After 5 days, a half-volume media was removed and suboptimal 
doses of rIL2 (10 ng/ml; Biosource, Invitrogen, UK) were added. Cul-
tures were continued for an additional 7 days. On the 12th day, fresh 
media supplemented with rIL2 was added in the presence of 105 
autologous-mitomycin-treated PBMCs. Finally (on the 19th day of 
culture) Pru p 3-TCLs (5 x 104 cells per well) and their mitomycin-
treated PBMCs (105 cells per well) were seeded in 96 wells. Pru p 
3 (10 |jig/ml) or each peptide (1 |jig/ml) were added to the TCL cul-
ture in triplicate wells for 48 h. Within the last 16 h, [3H]-thymidine 
(0.5 uXi/well) was added, and the incorporated radioactivity was 
measured by scintillation counting. The stimulation index was cal-
culated as described above. In this case, a SI > 3 was considered a 
positive value for TCLs. 
Before counting, supernatants were recovered to quantify the 
cytokines (IL4 and IFN7) by ELISA assays. 
PBMCs 
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Fig. 1. Frequency (%) of positive responses of PBMCs and TCLs from patients and control subjects to Pru p 3 (Pp3) and its 17 synthetic derived peptides (pl-pl7) . Significant 
differences (p < 0.05) between both groups are marked (*). 
2.5. Location ofT-cell epitopes on the 3-D structure of Pru p 3 
Chain A of the X-ray structure, PDB code 2B5S (Pasquato et 
al., 2006), was used to locate peptides on the three dimensional 
structure and surface of Pru p 3. Molecular graphics in Fig. 1 were 
prepared with PyMOL 1.0 (pymol.sourceforge.net). 
2.6. Determination ofIL4 and IFNy levels in TCL cultures 
Fifty microliters of TCL-supernatants were used to quantify the 
cytokine levels by using matched antibody-pairs according to the 
manufacturer's instructions (sensitive limits: IL4, 0.6pg/ml; IFN7, 
2 pg/ml; Immuno Tools, Friesoythe, Germany). Cultures containing 
TCLs with mitomycin-treated PBMCs alone served as negative con-
trols. IFN7/IL4 ratios over 10, between 2 and 10 and less than 2, 
were respectively considered as Thl-, ThO- and Th2- responses. 
2.7. Phenotypic analysis of TCLs 
To analyze T-cell phenotypes, cells were stained with 20 fjuL of 
anti-CD4-fluorescein isothiocyanate, anti-CD8 phycoerithrin (PE) 
and anti-CD3-Cy5-PE reagent mixture (Affinity BioReagents, CO, 
USA) for 20min in the dark (300 xg, 5min) and washing with 
PBS, cells were suspended in 300 fjuL PBS buffer, and analyzed in 
a FACSort flow cytometer with the CellQuest Pro software (BD Bio-
sciences, Erembodegen, Belgium). 
2.8. Statistical analysis 
Proliferative responses (SI) to each antigen (Pru p 3 and each 
of the derived peptides) of patients and control subjects were 
compared (Fig. 2) by Mann-Whitney non-parametric U-test. Lev-
els of IL4 and IFN7 in supernatants of TCLs from patients and 
controls treated with Pru p 3 and each of the 17 derived pep-
tides (joint analysis of the 17 samples; Fig. 3) were compared 
by Krustal-Wallis one-way nonparametric ANOVA. A level of sig-
nificance <5% (p<0.05) was considered to be significant in both 
analysis. 
3. Results 
3A. T-cell epitope mapping: patients versus controls 
PBMCs from 18 peach-allergic patients sensitized to Pru p 3 and 
10 non-peach-allergic controls without Pru p 3 sensitization were 
cultured in the presence of the complete allergen or each of its 
17-derived synthetic peptides. Overall, the proliferative response 
observed against these antigens were roughly more similar 
in patients (mean: 9714cpm; range: 2440-23,327 cpm; back-
ground: 832cpm) than in control subjects (mean: 11,325; range: 
1331-20,005 cpm; background: 1859 cpm). The PBMC responses 
were analyzed by comparing the SI obtained with each antigen. 
The results are summarized in Table 1 and Fig. 2. Pru p 3 activated 
7 out of 18 (39%) and 3 out of 10 (30%) of PBMCs from patients 
and controls, respectively, resulted similarly to those reported for 
other allergens and groups of patients (Glaspole et al., 2005; Tanabe, 
2007). A fault in the cultures can be discarded, because commercial 
phytohemagglutinin (PHA) induced high responses in all PBMCs 
(mean: 37,787; range: 22,956-89,723 cpm; SI range: 27.6-107.8). 
PBMCs from patients displayed different responses to the 17-
derived synthetic peptides. Peptides 14 and 15 triggered the highest 
rate of activation (positive SI to at least one of them in 72% - 13 out 
of 18 - of PBMCs), being the only one reaching stimulation in more 
than 50% of the patients analyzed. Both contiguous peptides can 
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Fig. 2. Frequency {%) of positive levels of IL4 and IFN-y in TCL supernatants from patients and control subjects treated with rPru p 3 or its derived peptides (pooled data of 
the 17 synthetic peptides). Medians (D) and S.D.s (bars) were calculated from n = 14 for Pru p3 and n = 238 for peptides. Significant differences (p< 0.05) are indicated (*). 
Table 1 
Positive responses (stimulation index, SI) of PBMCs and TCLs from peach-allergic patients to purified Pru p 3 and synthetic peptides (1-17) covering its full amino acid 
sequence. The positive results are remarked by shadowings. 
PBMCs 
Peptide 
no./sequence 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
Patients no. 
Pru p ,* 
ITCGQVSSSL 
VSSSLAPCIP 
APCIPYTOGG 
YVRGGGAVPP 
GAVPPACCMG 
ACCHGIRNVN 
IRNVHHLART 
NLARTTPDRQ 
TPDRQAACMC 
AACNCLKQLS 
LKQLSASVPG 
ASVPGVHPNH 
VHPNNAAALP 
AAALPGKCGV 
GKCGVSIPYK 
SIPYKISAST 
ISASTHCATVK 
1 
2.1 
2.1 
2,0 
2.2 
2.4 
3,0 
3,8 
2 
2.0 
2,2 
2,2 
2,3 
2,1 
2,4 
3 
2,0 
2,3 
4 
2,2 
5 
2,8 
2,1 
2,8 
3.3 
3.3 
.1,9 
2.') 
6 
2.3 
3.2 
2,9 
3,5 
2,4 
2.6 
3.0 
2,5 
3,2 
7 
2,0 
2,3 
2,4 
2.(5 
8 
2.7 
2,7 
2,0 
9 
3.1 
2.2 
28 
2.4 
2,3 
10 
2.0 
2,0 
2.3 
2.2 
2.4 
11 
2.9 
2,0 
12 
2.2 
2.7 
2.5 
2.0 
2.1 
2.0 
2,0 
2.2 
2,4 
4,0 
2,3 
13 
2.4 
2,6 
2.4 
2,1 
14 
2, 
2,2 
2,6 
2,3 
2,3 
2,5 
2,3 
2,8 
15 
2, 
2,1 
2,4 
16 
2,0 
2.3 
2.7 
2,6 
17 
2,2 
2.4 
2.3 
3,1 
8.3 
18 
2,2 
1,0 
2,4 
9.8 
2,0 
2,5 
a* 
39 
17 
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11 
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22 
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22 
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33 
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A SI > 2 for PBMCs and SI >3 for TCLs was considered positive, "a and b are the frequency (%) of positive responses to Pru p 3 or to each peptide for PBMCs or TCLs, respectively. 
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Fig. 3. Location on the 3-D structure of Pru p 3 of T-cell epitopes Pru p 325-35 (blue) and Pru p 365-so (green). (A) Amino acid sequence of Pru p 3, remarking the T-epitopes 
described in the present study. (B) Ribbon diagram showing amino acid side chains. The labels denote the four helices and C terminus. (C) Molecular surface (wireframe) 
showing the areas covered by the T-cell epitopes (solid) at the orientation in B. 
be considered as a single T-cell epitope: Pru p 365-so- The rest of 
peptides developed positive responses from 45% to 0% of PBMCs 
(Table 1). A similar pattern was found in the control group for most 
of the synthetic peptides, except for peptide 10 (Fig. 2, PBMCs), 
which provoked stimulation (SI > 2) in 70% of control subjects, but 
only in 39% of PBMCs from patients. In spite of the statistical sig-
nificance of this difference (p = 0.0083), the number of non-peach 
allergic subjects analyzed should be increased to define Pru p 345_55 
(peptide 10) as a non-allergic T-cell epitope. On the other hand, Pru 
p 365-so (peptides 14 and 15) was also recognized by approximately 
90% of PBMCs from control subjects. 
TCLs were produced by a long-time culture with Pru p 3 of 
PBMCs from nine patients and five controls subjects. Their prolifer-
ative response induced by the full allergen and its derived peptides 
are summarized in Table 1 (TCLs) and Fig. 2 (TCLs). The quantita-
tive response was similar in both groups (patients, mean: 8813 cpm, 
range: 2493-30,304 cpm, background: 1048 cpm; controls, mean: 
9120cpm, range: 1232-41,638 cpm, background: 1253), as well as 
the T-cell phenotype, which showed the same CD4+/CD8+ ratio 
(65%/35%). In contrast with the behaviour exhibited by PBMCs, all 
the patients' TCLs were activated by Pru p 3 (100%), while only 20% 
were activated in control subjects. 
Two main T-cell epitopes were identified analyzing the TCLs 
from patients: Pru p 365-so (SI > 3 in 78% of lines), previously located 
in the screening of PBMCs, and Pru p 325-35 by TCLs and PBMCs (67% 
versus 22%), indicated a higher specificity and a lower activity than 
Pru p 365_80- The latter also stimulated all five TCLs from control 
subjects, which were also activated by Pru p 330-40 (peptide 7) and 
Pru p 350-60 (peptide 11) in four out of five (80%) samples. Inter-
estingly, peptide 7 is contiguous and shares 5 amino acid residues 
with Pru p 325-35, the second T-cell epitope identified by analysis 
of TCLs from patients (see above). The same is true for peptide 11 
with respect to Pru p 345_55 (peptide 10), which had the highest 
stimulation rate to PBMCs from control subjects. 
Both of major T-cell epitopes of Pru p 3 were located on the 3-D 
structure of the peach allergen (Fig. 1) in the immediate vicinity 
of the IgE-binding regions described before (Garcia-Casado et al., 
2003; Pacios et al., 2008). Pru p 325-35 spans virtually all the helix 
H2 (25-36) and hence, it shows alternating buried and exposed 
residues. Pru p 365-so spans part of helix H4 (63-73) and a large seg-
ment of the C-terminal coil (74-91). Contrarily to Pru p 325-35, the 
latter T-cell epitope is mostly composed of exposed residues even 
though it shows predominance of hydrophobic amino acids. How-
ever, four residues (A66, L69,177, and Y79) are almost completely 
buried. 
3.2. IL4 and IFNy levels in TCL cultures indicate a differential type 
of T-cell response to Pru p 3 in patients and control subjects 
Supernatants of TCL cultures treated with Pru p 3 or its derived 
peptides were recovered to quantify the production of IL4 and IFN7, 
used as molecular markers of a Th2 or Thl response, respectively 
(Fig. 3). Patients' TCLs produced mainly IL4, with an IFN7/IL4 ratio 
lower than 2. In contrast, control subjects yielded a high amount 
of IFN7 and an IFN7/IL4 ratio higher than 11. These differences 
between patients and controls were non-statistically significant for 
Pru p 3, probably due to the limited number of samples analyzed, 
but were clearly significant (p<0.05) for both IL4 and IFN7 levels, 
as well as the IFN7/IL4 ratio, considering the pooled data observed 
in TCL cultures stimulated with each synthetic peptide (Fig. 3). This 
scenario was further confirmed by the analysis of cytokine levels in 
TCL supernatants treated with Pru p 3 (Table 2), indicated a Th2 type 
response in most patients, and a Thl type in most control subjects. 
A ThO response was detected in two cases from each the patient 
and control group. 
4. Discussion 
Allergies are on the rise, becoming an important health problem 
in western countries. Over 25% of the population suffers from IgE-
mediated allergic symptoms (Burks and Ballmer-Weber, 2006). The 
search of new tools for diagnosis and treatment would improve the 
life-quality of patients. In the last decade, new concepts of specific 
immunotherapy have evolved based on recombinant expression of 
allergens. Hypoallergenic isoforms or mutants with reduced IgE-
binding capacity would enable the use of a specific, safer and more 
efficient immunotherapy in the future (Woodfolk, 2007; Wagner et 
al., 2008). 
The involvement of CD4+ T-lymphocytes in the hypersensitive 
type I reactions is well established (Abbas et al., 1996; Thomas et 
Table 2 
IL4 and INF-y levels in TCL supernatants from patients and control subjects after 
stimulation with rPru p 3 Cytokine. 
Cytokine production3 
TCL derived from: 
Patient 6 
Patient 7 
Patient 8 
Patient 9 
Patient 10 
Patient 11 
Patient 12 
Patient 13 
Patient 14 
Control 3 
Control 4 
Control 5 
Control 6 
Control 7 
IFN-7(pg/ml) 
40 
200 
50 
300 
2200 
800 
50 
110 
300 
1100 
1600 
5000 
340 
100 
IL4 (pg/ml) 
2,500 
3,000 
2,000 
2,000 
10,000 
1,000 
50 
3,000 
40 
26 
150 
700 
100 
50 
Th subsetb 
2 
2 
2 
2 
2 
2 
0 
2 
0 
1 
1 
1 
0 
0 
1
 Means (n = 3). 
b
 An INF7/IL4 ratio >10, from 2 to 10, and <2 was considered a Thl, ThO, and Th2 
response, respectively. 
al., 2004). T-cells also contribute to induce tolerance to specific 
immunotherapy. During the vaccination process, a typical aller-
gic Th2 response changes to a Thl, and, finally, a suppression of 
allergen-specific T-cell responses has been observed (Bohle, 2006, 
2007; Woodfolk, 2007). Evaluation of immunotherapies using pep-
tides is generating great expectations. The challenge with T-peptide 
epitopes would result in stimulation of the T-cells, but no activa-
tion of mast cells and basophiles (Haselden et al., 2001; Smith and 
Larche, 2004). Therefore, it seems crucial to identify the dominant 
T-cell epitopes of the major peach allergen Pru p 3, in order to 
develop a T-cell targeted vaccine to be used for allergic patients 
to this fruit. 
The aim has been approached by proliferation assays of PBMCs 
and TCLs from clinically verified peach-allergic patients sensitized 
to Pru p 3. These PBMCs exhibited a moderate Pru p 3-specific acti-
vation (39%). This low-cellular response could be explained as a 
result of suppression mediated by immunoregulatory mechanism 
(Zeiler et al., 1999; Glaspole et al., 2005). However, a further step 
selecting Pru p 3-specific TCLs from some of the same patients, 
rendered CD4+ T-cell clones, most with a Th2 cytokine profile, and 
all of them activated by Pru p 3. Taking into account the results 
of the whole set of proliferation assays testing the synthetic pep-
tides which covered the full Pru p 3 amino acid sequence, two T-cell 
epitopes have been uncovered. Pru p 365-80. defined by two con-
secutive immunodominant peptides, emerged as a major epitope 
recognized by 72% of PBMCs and over 78% of TCLs from patients. Pru 
P 325-35 represents a second T-cell epitope, pointed out exclusively 
by TCLs (67% of positive responses). Remarkably, both sequential 
regions are localized in the 3-D structure of the peach allergen near 
its IgE epitopes previously described (Garcia-Casado et al., 2003; 
Pacios et al., 2008). Thus, Pru p 365-so overlaps a conformational IgE 
epitope (Pacios et al., 2008), whereas Pru p 325-35 covers the first 
sequential (positions 23-36) epitope identified by Garcia-Casado et 
al. (2003). Pru p 325-35 comprises alternating buried and exposed 
residues, whereas Pru p 365_8o mostly faces the clashes with the 
solvent spite its hydrophobic residue predominance. However, the 
significance of buried residues in both T-cell epitopes suggests that 
sequential issues instead of precise surface location might be more 
important in the activation of the T-cell response. 
Interestingly, the analysis of PBMCs and TCLs from 10 con-
trol volunteers without peach allergy non-sensitized to Pru p 3, 
roughly detected the same reactive synthetic peptides than those 
described above for the patient group. Pru p 365_8o was the more 
active sequential region activating PBMCs and TCLs from the con-
trol group, and a second active amino acid region, Pru p 330-40, 
overlaps with the second T-cell epitope localized when assaying 
patients' TCLs. Additionally, Pru p 350_6o was recognized by control 
subjects, but not by PBMCs or TCLs derived from patients. Poten-
tial T-cell epitopes of other allergens, such as Art v 1 and Bet v 1, 
have been reported to also stimulate T-cell from both patients and 
control subjects (Ebner et al., 1995; Haselden et al., 2001; Jahn-
Schmid et al., 2002; Glaspole et al., 2005). This fact suggests that the 
switch to allergic tolerance must not operate in the antigen-T-cell 
recognition, but in a subsequent step. A higher IFN7/IL4 ratio was 
observed in the controls in comparison with the patients' results. 
The majority of allergen-specific TCLs derived from allergic indi-
viduals displayed a Th2-like pattern of cytokine production, while 
non-allergic TCLs showed a Thl -like pattern of cytokines. This dif-
ference could explain the response of controls versus patients: since 
the former could tolerate Pru p 3, the latter would react by induc-
ing an allergic response (Schade et al., 2000; Turcanu et al., 2008). 
The difference in cytokine responses between control and peach-
allergic subjects does not seem to be based on different genetic 
backgrounds, because TCLs from both groups displayed a similar 
CD4+/CD8+ rate, and two control individuals allergic to grass pollen 
(control 5 and control 7 in Table 2) showed a Thl and ThO response, 
respectively, according to their IFN7/IL4 ratio. 
Summarizing, a limited number of T-cell epitopes are present 
in the peach allergen Pru p 3, the sequential Pru p 365-so being 
particularly relevant. These epitopes lead to activation of different 
Th subtypes in patients (Th2- response) and in peach non-allergic 
control subjects (Thl- response). The characterization of T-cell 
epitopes has implications for future developments in specific 
immunotherapy for type I allergy. The immunodominant T-cell epi-
tope identified in Pru p 3 may be a suitable candidate for peptide 
treatment of peach allergy. 
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